Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 253 to 259 of 259 entries
Sorted by: Best Match Show Resources per page
MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function.

Immunity

Sugiura A, Andrejeva G, Voss K, Heintzman DR, Xu X, Madden MZ, Ye X, Beier KL, Chowdhury NU, Wolf MM, Young AC, Greenwood DL, Sewell AE, Shahi SK, Freedman SN, Cameron AM, Foerch P, Bourne T, Garcia-Canaveras JC, Karijolich J, Newcomb DC, Mangalam AK, Rabinowitz JD, Rathmell JC.
PMID: 34767747
Immunity. 2021 Nov 03; doi: 10.1016/j.immuni.2021.10.011. Epub 2021 Nov 03.

Antigenic stimulation promotes T cell metabolic reprogramming to meet increased biosynthetic, bioenergetic, and signaling demands. We show that the one-carbon (1C) metabolism enzyme methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) regulates de novo purine synthesis and signaling in activated T cells to...

Cite
Sugiura A, Andrejeva G, Voss K, et al. MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function. Immunity. 2021;doi: 10.1016/j.immuni.2021.10.011.
Sugiura, A., Andrejeva, G., Voss, K., Heintzman, D. R., Xu, X., Madden, M. Z., Ye, X., Beier, K. L., Chowdhury, N. U., Wolf, M. M., Young, A. C., Greenwood, D. L., Sewell, A. E., Shahi, S. K., Freedman, S. N., Cameron, A. M., Foerch, P., Bourne, T., Garcia-Canaveras, J. C., Karijolich, J., Newcomb, D. C., Mangalam, A. K., Rabinowitz, J. D., & Rathmell, J. C. (2021). MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function. Immunity, . https://doi.org/10.1016/j.immuni.2021.10.011
Sugiura, Ayaka, et al. "MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function." Immunity vol. (2021). doi: https://doi.org/10.1016/j.immuni.2021.10.011
Sugiura A, Andrejeva G, Voss K, Heintzman DR, Xu X, Madden MZ, Ye X, Beier KL, Chowdhury NU, Wolf MM, Young AC, Greenwood DL, Sewell AE, Shahi SK, Freedman SN, Cameron AM, Foerch P, Bourne T, Garcia-Canaveras JC, Karijolich J, Newcomb DC, Mangalam AK, Rabinowitz JD, Rathmell JC. MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function. Immunity. 2021 Nov 03; doi: 10.1016/j.immuni.2021.10.011. Epub 2021 Nov 03. PMID: 34767747.
Copy Download .nbib Format: NLM
Erratum to: Multivalve infective endocarditis in intravenous drug using patients: an epidemiological study.

QJM : monthly journal of the Association of Physicians

Khan I, Brookes E, Yaftian N, Wilson A, Darby J, Newcomb A.
PMID: 34718803
QJM. 2021 Oct 27; doi: 10.1093/qjmed/hcab243. Epub 2021 Oct 27.

No abstract available.

Cite
Khan I, Brookes E, Yaftian N, et al. Erratum to: Multivalve infective endocarditis in intravenous drug using patients: an epidemiological study. QJM. 2021;doi: 10.1093/qjmed/hcab243.
Khan, I., Brookes, E., Yaftian, N., Wilson, A., Darby, J., & Newcomb, A. (2021). Erratum to: Multivalve infective endocarditis in intravenous drug using patients: an epidemiological study. QJM : monthly journal of the Association of Physicians, . https://doi.org/10.1093/qjmed/hcab243
Khan, Isa, et al. "Erratum to: Multivalve infective endocarditis in intravenous drug using patients: an epidemiological study." QJM : monthly journal of the Association of Physicians vol. (2021). doi: https://doi.org/10.1093/qjmed/hcab243
Khan I, Brookes E, Yaftian N, Wilson A, Darby J, Newcomb A. Erratum to: Multivalve infective endocarditis in intravenous drug using patients: an epidemiological study. QJM. 2021 Oct 27; doi: 10.1093/qjmed/hcab243. Epub 2021 Oct 27. PMID: 34718803.
Copy Download .nbib Format: NLM
Asthma Risk Among Individuals With Androgen Receptor Deficiency.

JAMA pediatrics

Gaston B, Marozkina N, Newcomb DC, Sharifi N, Zein J.
PMID: 33844005
JAMA Pediatr. 2021 Jul 01;175(7):743-745. doi: 10.1001/jamapediatrics.2021.0281.

No abstract available.

Cite
Gaston B, Marozkina N, Newcomb DC, et al. Asthma Risk Among Individuals With Androgen Receptor Deficiency. JAMA Pediatr. 2021;175(7):743-745doi: 10.1001/jamapediatrics.2021.0281.
Gaston, B., Marozkina, N., Newcomb, D. C., Sharifi, N., & Zein, J. (2021). Asthma Risk Among Individuals With Androgen Receptor Deficiency. JAMA pediatrics, 175(7), 743-745. https://doi.org/10.1001/jamapediatrics.2021.0281
Gaston, Benjamin, et al. "Asthma Risk Among Individuals With Androgen Receptor Deficiency." JAMA pediatrics vol. 175,7 (2021): 743-745. doi: https://doi.org/10.1001/jamapediatrics.2021.0281
Gaston B, Marozkina N, Newcomb DC, Sharifi N, Zein J. Asthma Risk Among Individuals With Androgen Receptor Deficiency. JAMA Pediatr. 2021 Jul 01;175(7):743-745. doi: 10.1001/jamapediatrics.2021.0281. PMID: 33844005; PMCID: PMC8042560.
Copy Download .nbib Format: NLM
Protocol for #iBeatCRC: a community-based intervention to increase early-onset colorectal cancer awareness using a sequential explanatory mixed-methods approach.

BMJ open

Rogers CR, Brooks E, Curtin K, De Vera MA, Qeadan F, Rogers TN, Petersen E, Gallagher P, Pesmen C, Johnson W, Henley C, Hickman W, Newcomb E, Korous KM, Handley MA.
PMID: 34862279
BMJ Open. 2021 Dec 03;11(12):e048959. doi: 10.1136/bmjopen-2021-048959.

INTRODUCTION: Th last two decades have seen a twofold increase in colorectal cancer (CRC) incidence among individuals under the recommended screening age of 50 years. Although the origin of this early-onset CRC (EOCRC) spike remains unknown, prior studies have...

Cite
Rogers CR, Brooks E, Curtin K, et al. Protocol for #iBeatCRC: a community-based intervention to increase early-onset colorectal cancer awareness using a sequential explanatory mixed-methods approach. BMJ Open. 2021;11(12):e048959doi: 10.1136/bmjopen-2021-048959.
Rogers, C. R., Brooks, E., Curtin, K., De Vera, M. A., Qeadan, F., Rogers, T. N., Petersen, E., Gallagher, P., Pesmen, C., Johnson, W., Henley, C., Hickman, W., Newcomb, E., Korous, K. M., & Handley, M. A. (2021). Protocol for #iBeatCRC: a community-based intervention to increase early-onset colorectal cancer awareness using a sequential explanatory mixed-methods approach. BMJ open, 11(12), e048959. https://doi.org/10.1136/bmjopen-2021-048959
Rogers, Charles R, et al. "Protocol for #iBeatCRC: a community-based intervention to increase early-onset colorectal cancer awareness using a sequential explanatory mixed-methods approach." BMJ open vol. 11,12 (2021): e048959. doi: https://doi.org/10.1136/bmjopen-2021-048959
Rogers CR, Brooks E, Curtin K, De Vera MA, Qeadan F, Rogers TN, Petersen E, Gallagher P, Pesmen C, Johnson W, Henley C, Hickman W, Newcomb E, Korous KM, Handley MA. Protocol for #iBeatCRC: a community-based intervention to increase early-onset colorectal cancer awareness using a sequential explanatory mixed-methods approach. BMJ Open. 2021 Dec 03;11(12):e048959. doi: 10.1136/bmjopen-2021-048959. PMID: 34862279; PMCID: PMC8647393.
Copy Download .nbib Format: NLM
Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago.

Annals of epidemiology

Mustanski B, Saber R, Ryan DT, Benbow N, Madkins K, Hayford C, Newcomb ME, Schrock JM, Vaught LA, Reiser NL, Velez MP, Hsieh RR, Demonbreun AR, D'Aquila R, McNally EM, McDade TW.
PMID: 34728335
Ann Epidemiol. 2021 Oct 30; doi: 10.1016/j.annepidem.2021.10.006. Epub 2021 Oct 30.

To date, COVID-19 case rates are disproportionately higher in Black and Latinx communities across the US, leading to more hospitalizations and deaths in those communities. These differences in case rates are evident in comparisons of Chicago neighborhoods with differing...

Cite
Mustanski B, Saber R, Ryan DT, et al. Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago. Ann Epidemiol. 2021;doi: 10.1016/j.annepidem.2021.10.006.
Mustanski, B., Saber, R., Ryan, D. T., Benbow, N., Madkins, K., Hayford, C., Newcomb, M. E., Schrock, J. M., Vaught, L. A., Reiser, N. L., Velez, M. P., Hsieh, R. R., Demonbreun, A. R., D'Aquila, R., McNally, E. M., & McDade, T. W. (2021). Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago. Annals of epidemiology, . https://doi.org/10.1016/j.annepidem.2021.10.006
Mustanski, Brian, et al. "Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago." Annals of epidemiology vol. (2021). doi: https://doi.org/10.1016/j.annepidem.2021.10.006
Mustanski B, Saber R, Ryan DT, Benbow N, Madkins K, Hayford C, Newcomb ME, Schrock JM, Vaught LA, Reiser NL, Velez MP, Hsieh RR, Demonbreun AR, D'Aquila R, McNally EM, McDade TW. Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago. Ann Epidemiol. 2021 Oct 30; doi: 10.1016/j.annepidem.2021.10.006. Epub 2021 Oct 30. PMID: 34728335; PMCID: PMC8557112.
Copy Download .nbib Format: NLM
Switching of Self-Assembly in a Peptide Nanostructure with a Specific Enzyme.

Soft matter

Webber MJ, Newcomb CJ, Bitton R, Stupp SI.
PMID: 22408645
Soft Matter. 2011 Oct 21;7(20):9665-9672. doi: 10.1039/c1sm05610g.

Peptide self-assembly has been shown to be a useful tool for the preparation of bioactive nanostructures, and recent work has demonstrated their potential as therapies for regenerative medicine. In principle, one route to make these nanostructures more biomimetic would...

Cite
Webber MJ, Newcomb CJ, Bitton R, et al. Switching of Self-Assembly in a Peptide Nanostructure with a Specific Enzyme. Soft Matter. 2011;7(20):9665-9672doi: 10.1039/c1sm05610g.
Webber, M. J., Newcomb, C. J., Bitton, R., & Stupp, S. I. (2011). Switching of Self-Assembly in a Peptide Nanostructure with a Specific Enzyme. Soft matter, 7(20), 9665-9672. https://doi.org/10.1039/c1sm05610g
Webber, Matthew J, et al. "Switching of Self-Assembly in a Peptide Nanostructure with a Specific Enzyme." Soft matter vol. 7,20 (2011): 9665-9672. doi: https://doi.org/10.1039/c1sm05610g
Webber MJ, Newcomb CJ, Bitton R, Stupp SI. Switching of Self-Assembly in a Peptide Nanostructure with a Specific Enzyme. Soft Matter. 2011 Oct 21;7(20):9665-9672. doi: 10.1039/c1sm05610g. PMID: 22408645; PMCID: PMC3293180.
Copy Download .nbib Format: NLM
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH.
PMID: 34112709
Clin Cancer Res. 2021 Aug 15;27(16):4574-4586. doi: 10.1158/1078-0432.CCR-21-1047. Epub 2021 Jun 10.

PURPOSE: CD40 activation is a novel clinical opportunity for cancer immunotherapy. Despite numerous active clinical trials with agonistic CD40 monoclonal antibodies (mAb), biological effects and treatment-related modulation of the tumor microenvironment (TME) remain poorly understood.PATIENTS AND METHODS: Here, we...

Cite
Byrne KT, Betts CB, Mick R, et al. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021;27(16):4574-4586doi: 10.1158/1078-0432.CCR-21-1047.
Byrne, K. T., Betts, C. B., Mick, R., Sivagnanam, S., Bajor, D. L., Laheru, D. A., Chiorean, E. G., O'Hara, M. H., Liudahl, S. M., Newcomb, C., Alanio, C., Ferreira, A. P., Park, B. S., Ohtani, T., Huffman, A. P., Väyrynen, S. A., Dias Costa, A., Kaiser, J. C., Lacroix, A. M., Redlinger, C., Stern, M., Nowak, J. A., Wherry, E. J., Cheever, M. A., Wolpin, B. M., Furth, E. E., Jaffee, E. M., Coussens, L. M., & Vonderheide, R. H. (2021). Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(16), 4574-4586. https://doi.org/10.1158/1078-0432.CCR-21-1047
Byrne, Katelyn T, et al. "Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,16 (2021): 4574-4586. doi: https://doi.org/10.1158/1078-0432.CCR-21-1047
Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021 Aug 15;27(16):4574-4586. doi: 10.1158/1078-0432.CCR-21-1047. Epub 2021 Jun 10. PMID: 34112709; PMCID: PMC8667686.
Copy Download .nbib Format: NLM
Showing 253 to 259 of 259 entries